SAN DIEGO, Nov. 21 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals,
Inc. (Nasdaq: AMLN) will be presenting at its Research & Development (R&D)
Day on Wednesday, November 28, 2007 at 10:00 a.m. ET at the Grand Hyatt
Hotel in New York.
"Amylin is focused on bringing innovative medicines with life-changing
therapeutic potential to patients through our sustainable approach to the
discovery and development of drugs," said Daniel M. Bradbury, President and
Chief Executive Officer of Amylin Pharmaceuticals. "At this year's R&D Day,
we look forward to presenting an update on our opportunities to build
near-term value with our marketed products, discussing our recent exciting
clinical results from the once-weekly exenatide program and the
pramlintide/leptin program, and providing insights into our research
strategy."
The agenda for this year's R&D Day includes presentations by the
following officers of Amylin Pharmaceuticals:
-- Introduction
Daniel M. Bradbury
President and Chief Executive Officer
-- Diabetes Programs
Orville Kolterman, MD
Senior Vice President of Clinical and Regulatory Affairs
-- Obesity Programs
Alain Baron, MD
Senior Vice President of Research
-- Discovery Research
Michael Hanley, PhD
Vice President of Discovery Research
A question and answer session will follow the presentations.
The presentation will be webcast live through Amylin's corporate
website and a recording will be made available following the close of the
call. To access the webcast, please log on to http://www.amylin.com
approximately fifteen minutes prior to the call to register, download and
install any necessary audio software.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals, Inc. is a biopharmaceutical company committed
to improving lives through the discovery, development and commercialization
of innovative medicines. Amylin has developed and gained approval for two
first- in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate)
injection and BYETTA(R) (exenatide) injection. Amylin's research and
development activities leverage the company's expertise in metabolism to
develop potential therapies to treat diabetes and obesity. Amylin is
headquartered in San Diego, California with over 1,800 employees
nationwide. Further information on Amylin Pharmaceuticals is available at
http://www.amylin.com.
SOURCE Amylin Pharmaceuticals, Inc.
 back to top
Related links:
http://www.amylin.com
CONTACT:
Alice Bahner Izzo of Amylin Pharmaceuticals,
Inc., +1-858-642-7272, Cell, +1-858-232-9072,
alice.izzo@amylin.com; or Rachel Martin of Edelman,
+1-323-202-1031, Cell, +1-323-373-5556,
rachel.martin@edelman.com, for Amylin Pharmaceuticals, Inc.
|
